Comparison of Insulin Detemir and Insulin Glargine on Glycemic Variability in Patients with Type 1 and Type 2 Diabetes

Abstract

Aims: To compare the glycemic variability of insulin detemir and insulin glargine in type 1 and type 2 diabetic patients.

Methods: 15 type 1 and 14 type 2 diabetic patients receiving intensive insulin therapy with insulin glargine were enrolled. Before and after switching insulin glargine to insulin detemir, we assessed fasting glucose variability using the standard deviation (SD) and the coefficient of variance (CV) of self-monitored fasting blood sugar (FBS) levels.

Results: The SD and CV values were significantly decreased in type 1 diabetes after switching the therapy, though there was no significant difference in type 2 diabetes. The frequency of hypoglycemia was decreased in type 1 diabetes and there was no change in type 2 diabetes. The changes of the CV value also showed significant positive correlation with fasting serum CPR levels in all patients and total insulin dose in type 1 diabetes. The changes of frequency of hypoglycemia showed significant positive correlation with total and basal insulin dose adjusted for body weight in type 1 diabetes.

Conclusion: The present study demonstrated lower within-subject variability of insulin detemir compared to insulin glargine, suggesting that the basal insulin replacement with insulin detemir may provide a useful therapeutic strategy for uncontrolled type 1 diabetes with high glucose variability.

insulin detemir - insulin glargine - hypoglycemia - glycemic variability - diabetes mellitus

References

• 1 Bonds DE, Kurashige EM, Bergenstal R. et al . Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.  Am J Cardiol. 2007;  99 80i-89i
• 2 Cefalu WT, Watson K. Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think?.  Diabetes. 2008;  57 1163-1165
• 3 Danne T, Datz N, Endahl L. et al . Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial*.  Pediatr Diabetes. 2008;  9 554-560
• 4 Heise T, Nosek L, Ronn BB. et al . Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.  Diabetes. 2004;  53 1614-1620
• 5 Hermansen K, Davies M, Derezinski T. et al . A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.  Diabetes Care. 2006;  29 1269-1274
• 6 King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.  Diabetes Obes Metab. 2009;  11 69-71
• 7 Klein O, Lynge J, Endahl L. et al . Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.  Diabetes Obes Metab. 2007;  9 290-299
• 8 Kolendorf K, Ross GP, Pavlic-Renar I. et al . Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.  Diabet Med. 2006;  23 729-735
• 9 Meneghini LF, Rosenberg KH, Koenen C. et al . Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.  Diabetes Obes Metab. 2007;  9 418-427
• 10 Moberg EA, Lins PE, Adamson UK. Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified insulin regimens.  Diabete Metab. 1994;  20 546-552
• 11 Muggeo M, Zoppini G, Bonora E. et al . Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.  Diabetes Care. 2000;  23 45-50
• 12 Pieber TR, Treichel HC, Hompesch B. et al . Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.  Diabet Med. 2007;  24 635-642
• 13 Porcellati F, Rossetti P, Busciantella NR. et al . Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.  Diabetes Care. 2007;  30 2447-2452
• 14 Ratner RE, Hirsch IB, Neifing JL. et al . Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetesU.S. Study Group of Insulin Glargine in Type 1 Diabetes.  Diabetes Care. 2000;  23 639-643
• 15 Rosenstock J, Davies M, Home PD. et al . A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.  Diabetologia. 2008;  51 408-416
• 16 Vague P, Selam JL, Skeie S. et al . Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.  Diabetes Care. 2003;  26 590-596
• 17 White NH, Chase HP. et al . Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.  Diabetes Care. 2009;  32 387-393

Correspondence